As of 2025-09-17, the EV/EBITDA ratio of ACADIA Pharmaceuticals Inc (ACAD) is -30.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acadia's latest enterprise value is 3,788.65 mil USD. Acadia's TTM EBITDA according to its financial statements is -125.24 mil USD. Dividing these 2 quantities gives us the above Acadia EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 15.7x | 14.5x |
| Forward P/E multiples | 14.8x - 16.9x | 15.8x |
| Fair Price | (8.44) - 29.16 | 9.02 |
| Upside | -135.2% - 21.7% | -62.3% |
| Date | EV/EBITDA |
| 2025-09-15 | -31.21 |
| 2025-09-12 | -29.78 |
| 2025-09-11 | -30.57 |
| 2025-09-10 | -30.03 |
| 2025-09-09 | -31.44 |
| 2025-09-08 | -32.18 |
| 2025-09-05 | -32.00 |
| 2025-09-04 | -32.32 |
| 2025-09-03 | -32.62 |
| 2025-09-02 | -32.58 |
| 2025-08-29 | -32.98 |
| 2025-08-28 | -33.31 |
| 2025-08-27 | -33.77 |
| 2025-08-26 | -32.62 |
| 2025-08-25 | -32.08 |
| 2025-08-22 | -32.65 |
| 2025-08-21 | -31.36 |
| 2025-08-20 | -31.57 |
| 2025-08-19 | -31.61 |
| 2025-08-18 | -31.73 |
| 2025-08-15 | -32.10 |
| 2025-08-14 | -31.02 |
| 2025-08-13 | -31.83 |
| 2025-08-12 | -32.26 |
| 2025-08-11 | -31.41 |
| 2025-08-08 | -31.11 |
| 2025-08-07 | -30.84 |
| 2025-08-06 | -30.03 |
| 2025-08-05 | -29.82 |
| 2025-08-04 | -30.36 |
| 2025-08-01 | -29.67 |
| 2025-07-31 | -30.08 |
| 2025-07-30 | -29.67 |
| 2025-07-29 | -28.46 |
| 2025-07-28 | -28.45 |
| 2025-07-25 | -29.29 |
| 2025-07-24 | -29.02 |
| 2025-07-23 | -29.32 |
| 2025-07-22 | -28.38 |
| 2025-07-21 | -27.99 |
| 2025-07-18 | -28.36 |
| 2025-07-17 | -28.35 |
| 2025-07-16 | -28.35 |
| 2025-07-15 | -27.62 |
| 2025-07-14 | -27.46 |
| 2025-07-11 | -26.24 |
| 2025-07-10 | -27.69 |
| 2025-07-09 | -27.03 |
| 2025-07-08 | -26.29 |
| 2025-07-07 | -26.10 |